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Background: NUP98 gene rearrangements have been reported in acute myeloid leukemia, giving rise to fusion
proteins that seem to function as aberrant transcription factors, and are thought to be associated with poor
prognosis.
Findings: A patient with treatment-related acute myeloid leukemia presented a t(3;11)(p11;p15) as the only
cytogenetic abnormality. FISH and molecular genetic analyses identified a class 1 homeobox gene, POU1F1, located
on chromosome 3p11, as the fusion partner of NUP98. In addition, we have found that the patient harbored an
FLT3-ITD mutation, which most likely collaborated with the NUP98-POU1F1 fusion gene in malignant transformation.
Conclusions: We have identified POU1F1 as the NUP98 fusion partner in therapy-related AML with a t(3;11)(p11;
p15). This is the first POU family member identified as a fusion partner in human cancer.
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Acute myeloid leukemia (AML) is often associated with
chromosomal translocations, resulting in fusion genes
that have implications in disease prognosis and treat-
ment. Chromosomal translocations involving the NUP98
gene have been reported in a wide range of hematopoietic
malignancies, involving more than 20 different partner
genes to generate fusion proteins with abnormal function
[1]. The frequency of these rearrangements in AML is 1
to 2% and they seem to be associated with poor prognosis,
thus highlighting the relevance of identifying and charac-
terizing cases harboring such genetic alterations [1,2].
The NUP98 gene codes for a protein that is a compo-
nent of the nuclear pore complex (NPC) and contains
multiple nontandem GLFG repeats (Gly-Leu-Phe-Gly)
that are thought to function as docking sites to allow the
bidirectional transport of mRNA and proteins between
the nucleus and the cytoplasm [1]. The NUP98 protein is
also involved in cell cycle progression, mitotic spindle* Correspondence: manuel.teixeira@ipoporto.min-saude.pt
†Equal contributors
1Department of Genetics, Portuguese Oncology Institute, Rua Dr. António
Bernardino de Almeida, 4200-072 Porto, Portugal
3Institute of Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal
Full list of author information is available at the end of the article
© 2013 Lisboa et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orformation, and gene transcription [1]. All the transloca-
tions so far described involving the NUP98 gene result in
the fusion of its 50 region (coding for the GLFG repeats)
to the 30 region of the partner gene. The C-terminal
partners can be divided into two general classes: homeo-
domain (HD) proteins and non-HD proteins [1]. HD pro-
teins contain a DNA-binding domain (the HD domain)
that is in all instances retained in the fusion protein, with
its amino terminal region replaced by the GLFG repeats
of NUP98. The fusion protein seems to function as an
aberrant transcription factor, directly binding DNA to
activate gene transcription and leading to the deregulation
of HOXA cluster genes that are important for normal
hematopoietic differentiation [1,3].
A 57-year-old female was diagnosed with a breast
adenocarcinoma in 2001 (T1N0M0; treated with radical
mastectomy, followed by four courses of chemotherapy
with 5-fluorouracil, epirubicin, and cyclophosphamide,
radiotherapy and hormonotherapy with tamoxifen). In
2005, the patient developed leucocytosis associated with
asthenia and febrile syndrome and the diagnosis of
therapy-related AML was established (AML-M4 accord-
ing to the French-American-British classification). Blood
count was hemoglobin 11.0 g/dL, platelets 102 × 109/L,
and leukocytes 71 × 109/L with 13% circulating blastsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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She was treated with chemotherapy (cytarabine, dauno-
rubicin, and cyclosporin) and a complete response was
attained. The patient was proposed to bone marrow
transplantation, but no compatible donor was found.
Ten months later the patient showed evidence of
relapse with leukocytosis and thrombocytopenia and
died within five months.
The bone marrow karyotype revealed a t(3;11)(p11;
p15) as the sole cytogenetic abnormality in all 30 meta-
phases analyzed (Figure 1A), suggesting the involvement
of the NUP98 gene located in 11p15. The previous
knowledge that HD transcription factors are frequently
involved in rearrangements with the NUP98 gene, com-
bined with a GenBank search of putatively expressed
genes on chromosomal band 3p11, prompted us to
hypothesize that the NUP98 fusion partner was POU1F1.
FISH analysis revealed the presence of fusion signals on
the der (3) and on the der (11) chromosomes, strongly
suggesting the presence of a rearrangement involving
NUP98 and POU1F1 (Figure 1B).
RT-PCR with an antisense primer located on POU1F1
exon 5 and three NUP98 sense primers located on exons
9, 10, and 11 (Additional file 1) showed the presence
of PCR fragments suggestive of an NUP98-POU1F1
rearrangement resulting from fusion of NUP98 exon 11
with POU1F1 exon 5 (Figure 2A). Additional RT-PCR
analysis with sense primers located on NUP98 exons 9,Figure 1 Cytogenetic and fluorescence in situ hybridization studies o
following standard procedures. Chromosome banding analysis of the bone
was described according to ISCN [4]. A) Bone marrow karyotype obtained
chromosome abnormality, suggesting the involvement of the NUP98 gene
arrows. BAC clones for NUP98 and POU1F1 were selected using the UCSC H
Center. B) Dual color, dual fusion FISH analysis performed on metaphases u
green and for POU1F1 (CTD-2372C6) labeled in red, showed the presence o
signals on normal chromosomes 3 and 11, respectively.10, 11 and an antisense primer located on POU1F1 exon
4 and with a sense primer located on NUP98 exon 12
and antisense primers located on POU1F1 exons 4 and
5, gave additional support to this hypothesis, since no
amplification was observed (Figure 2A). Sequencing of
the amplification products followed by a BLAST search
confirmed that NUP98 exon 11 was fused in-frame with
nucleotide 730 of the POU1F1 transcript (GenBank ac-
cession no. NM_000306) (Figure 2B). For the detection
of the reciprocal POU1F1-NUP98 transcript a POU1F1
sense primer and a NUP98 antisense primer located on
exons 4 and 12, respectively, were used but no fusion
transcript could be detected (results not shown). This
fusion is expected to give rise to a chimeric fusion
protein where the N terminus of NUP98 is fused to the
C terminus of POU1F1 (Figure 2C). This is in agreement
with the results of all previously reported NUP98 fusions,
in which the C-terminal DNA binding homeodomain of
the homeobox protein is retained in the fusion protein
and the GLFG repeats of NUP98 replace the transactiva-
tion domain [1].
For the identification of the genomic breakpoints of the
NUP98-POU1F1 fusion, several primers were designed in
NUP98 intron 11 and POU1F1 intron 4 (Additional file 1).
When the NUP98_Fint11H sense primer was used in com-
bination with the POU1F1_Rint4A and POU1F1_Rint4B
antisense primers, amplification products of 412 bp and
603 bp were observed, respectively (Figure 2D). Partialf the AML patient. The bone marrow sample was cultured for 24 h
marrow was performed after Leichmann’s staining and the karyotype
by GTL banding technique exhibiting a t(3;11)(p11;p15) as the sole
located at 11p15. Derivative chromosomes 3 and 11 are marked with
uman Genome Browser and obtained from the BACPAC Resource
sing BAC probes for NUP98 (CTD-3082 N2, RP11-161I4) labeled in
f fusion signals on der(3) and der(11) and isolated red and green
Figure 2 (See legend on next page.)
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Figure 2 Characterization of the NUP98-POU1F1 fusion. A) RT-PCR analysis with one antisense primer on POU1F1 exon 5 and three sense
primers on NUP98 exons 9, 10, and 11 (lanes 3, 5, and 7) showed the presence of PCR fragments of 362, 242, and 101 bp, respectively, suggestive
of a fusion between NUP98 exon 11 and POU1F1 exon 5. Additional RT-PCR analysis with several NUP98 and POU1F1 primer combinations gave
additional support to this hypothesis since no amplification was observed (lanes 2, 4, 6, 8, and 9). Lane 10: RNA integrity check (370 bp B2M gene
fragment). Lanes 1 and 11: 100 bp molecular marker. B) Sequence analysis followed by a BLAST search confirmed that NUP98 exon 11 was fused
in-frame with nucleotide 730 of the POU1F1 transcript (arrow). C) Schematic representation of the NUP98, POU1F1, and the NUP98-POU1F1 fusion
proteins showing the relevant domains of the partner and chimeric proteins. D) Genomic breakpoint analysis with the NUP98_Fint11H sense
primer in combination with the POU1F1_Rint4B and POU1F1_Rint4A antisense primers gave origin to amplification products of 603 and 412 bp,
respectively (lanes 1 and 2). Lane 3: 100 bp molecular marker. E) Sequencing of the amplification products showed that the breakpoint was
located 7490 bp downstream of NUP98 exon 11 and 129 bp downstream of the start of POU1F1 exon 4 (arrow). F) Schematic representation of
the genomic DNA breakpoint (arrow) and nucleotide sequence of the genomic breakpoint of the translocation t(3;11) and corresponding normal
chromosomes 3 and 11.
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breakpoint was located 7490 bp downstream of NUP98
exon 11 and, interestingly, within POU1F1 exon 4, 129 bp
downstream of the start of POU1F1 exon 4, and no evi-
dence of mutation or deletion was detected in the break-
point region (Figure 2A and F). This leads to retention in
the genomic sequence of 36 nucleotides from POU1F1
exon 4 that are not included in the mature NUP98-
POU1F1 messenger RNA, probably as a result of the
removal of the splice acceptor site of POU1F1 intron 3.
Since FLT3-ITD mutations have been reported in more
than 50% of the patients with NUP98-HOX fusions [5],
we have searched for this abnormality in our patient using
the FLT3 Mutation Assay for Gel Detection (InVivoScribe
Technologies, San Diego, USA) according to the manufac-
turer’s instructions. We found an internal tandem muta-
tion of the FLT3 gene, as shown by the presence of an
amplification product of approximately 350 bp (Additional
file 2: Figure S1).
To our knowledge, this is the first time that POU1F1,
a POU class 1 homeobox gene, is reported as being
involved in a fusion gene in human cancer. POU1F1
belongs to the POU family of transcription factors that
plays a fundamental role in inhibition and promotion of
cell differentiation, as well as in the determination of cell
lineage and regulation of cell migration, survival and ter-
minal differentiation [6]. In adults, POU1F1 is expressed
in cells of the anterior pituitary gland, where it plays a
role in cellular commitment, differentiation and prolif-
eration, driving the expression of growth hormone, pro-
lactin, and thyroid-stimulating hormone β chain genes
[6]. POU1F1 expression has also been reported in
hematopoietic and lymphoid tissues [7], and its expres-
sion was correlated with increased cellular proliferation
in breast cancer and human myeloid leukemic cells, lead-
ing to the suggestion that POUF1 may be involved in the
regulation of cellular proliferation [8-10]. Since the
expression of NUP98-HOX chimeric genes seems to be
under the control of the NUP98 promoter [1], leading to
overexpression of the HD transcription factor, it is
expected that the same occurs in the rearrangement wehere describe, and that POU1F1 overexpression might
result in increased proliferation of leukemic cells.
Several lines of evidence have suggested that many of
the NUP98 fusion proteins can act as aberrant transcrip-
tion factors. It seems that a synergistic action between
NUP98 and the HD partner gene leads to the creation of
a unique protein with unique DNA targeting properties
and function, which can lead to leukemogenic trans-
formation [1]. Indeed, the NUP98 chimeric proteins not
only retain the N-terminal sequences that are respon-
sible for both DNA binding and transcription activation
through a “cryptic” transactivation domain [11-13], but
also the C-terminal region of the HD partner can dir-
ectly bind DNA and activate gene transcription [1]. Fur-
thermore, mouse models of NUP98-HOX fusions were
shown to induce leukemia with variable latency [1],
which was associated with deregulation of HOXA cluster
genes that are thought to play a key role in normal
hematopoietic differentiation [14]. Impaired terminal
differentiation of hematopoietic cells is a hallmark of
leukemia and, according to the two-hit model of
leukemogenesis, is classified as a type II mutation [15].
However, this model of leukemic transformation, al-
though overly simplified, requires the presence of a con-
comitant mutation leading to increased proliferation,
survival, or both (type I mutation) [15]. It seems that
NUP98-HOX fusions have the ability to initiate and
maintain a state of self-renewal necessary, but not suffi-
cient, for the development of leukemia [1]. Indeed, type
I mutations are common in NUP98 rearranged
leukemia, including mutations in the NRAS, KRAS, KIT,
WT1 and FLT3 genes [5,16]. The type I mutation in the
case we here present was the FLT3-ITD mutation,
which we hypothesize collaborated with the NUP98-
POU1F1 fusion in malignant transformation.
In summary, we have identified POU1F1 as the
NUP98 fusion partner in therapy-related AML with a
t(3;11)(p11;p15). This is the first POU family member
identified as a fusion partner in leukemia, and further
studies are necessary to uncover the precise role played
by this family of genes in this disease.
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Additional file 1: Oligonucleotide primers used in this study.
Additional file 2: Figure S1. Detection and analysis of the FLT3-ITD
mutation. Lane 1 and 8: 100 bp molecular marker. Lane 2: specimen
control size ladder with amplification products of approximately 100, 200,
300, 400 and 600 bp confirming the patient DNA sample integrity. Lanes
3 and 7: no template controls. Lane 4: presence of amplification products
of approximately 330 bp (the wild type allele) and a larger amplification
product corresponding to the detection of internal tandem duplication
(ITD) of the FLT3 gene. Lane 5: negative control (amplification of
polyclonal control DNA of approximately 330 bp). Lane 6: positive control
(amplification of clonal control DNA of approximately 360 bp).
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